CureVac (NASDAQ:CVAC – Get Free Report) shares hit a new 52-week low during trading on Wednesday . The company traded as low as $2.34 and last traded at $2.41, with a volume of 214016 shares trading hands. The stock had previously closed at $2.60.
Wall Street Analysts Forecast Growth
Separately, Guggenheim reissued a “neutral” rating on shares of CureVac in a report on Friday, April 5th.
Get Our Latest Analysis on CureVac
CureVac Stock Performance
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of CVAC. Ballentine Partners LLC acquired a new stake in shares of CureVac during the 1st quarter worth approximately $38,000. Platinum Investment Management Ltd. raised its position in shares of CureVac by 37.1% during the 4th quarter. Platinum Investment Management Ltd. now owns 497,906 shares of the company’s stock worth $2,096,000 after purchasing an additional 134,626 shares during the period. Aristides Capital LLC acquired a new stake in CureVac in the 4th quarter valued at approximately $100,000. Dynamic Technology Lab Private Ltd acquired a new stake in CureVac in the 4th quarter valued at approximately $160,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in CureVac in the 4th quarter valued at approximately $68,000. Institutional investors own 17.26% of the company’s stock.
About CureVac
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.
See Also
- Five stocks we like better than CureVac
- There Are Different Types of Stock To Invest In
- High-Yield Texas Instruments Could Hit New Highs Soon
- What Are Dividends? Buy the Best Dividend Stocks
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Investing in Travel Stocks Benefits
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.